PGNX Stock News 3.57 05/13/2014 17:04:27 Progenics Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Progenics Pharmaceuticals Inc (PGNX) 3.57 $PGNX

Stocks Analysis on Top Gainers -- Research on Progenics Pharma, Lionbridge Technologies, Nuverra Environmental Solutions, and Senomyx
PR Newswire - Mon May 12, 10:30AM CDT
The US markets saw a positive sentiment on Friday, May 9, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care, and Consumer Staples along with a drag from Utilities, Energy, and Financials sectors. A number of stocks saw large movements, including Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Lionbridge Technologies Inc. (NASDAQ: LIOX), Nuverra Environmental Solutions Inc. (NYSE: NES) and Senomyx Inc. (NASDAQ: SNMX). Free technical research on PGNX, LIOX, NES and SNMX can be downloaded upon signing up at:

Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
M2 - Mon May 12, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52w3s/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agonox - Camurus AB - Colby Pharmaceutical Company - Fountain Biopharma Inc. - MEI Pharma, Inc. - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. Drug Profiles: - cabazitaxel - pracinostat - leuprolide acetate - LU-901 - veliparib - Engineered Autologous T Cells [cyclophosphamide] - MEDI-6469 - CPC-410 - Actimab-P - Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - MIP-1095 - FB-704A - Ceramide Analogs - KGP-94 - Vaccine For Oncolytic Newcastle Disease Virus - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/f52w3s/metastatic

Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 09, 12:41PM CDT
Salix's (SLXP) first quarter 2014 earnings of 92 cents per share were far above the Zacks Consensus Estimate of 42 cents and the year-ago earnings of 53 cents per share.

Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Fri May 09, 6:31AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) today announced its results of operations for the quarter ended March 31.

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic

Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma

Progenics Pharmaceuticals Sets First Quarter 2014 Financial Results Call for May 9
GlobeNewswire - Thu May 01, 6:41AM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq GNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review first quarter 2014 financial results on Friday, May 9, at 8:30 a.m. ET.

Global Pheochromocytoma Global Clinical Trials Review 2014 - Espy the Top 15 Companies/Institutions
M2 - Wed Apr 30, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvv7qm/pheochromocytoma) has announced the addition of the "Pheochromocytoma Global Clinical Trials Review, H1, 2014" report to their offering. Pheochromocytoma Global Clinical Trials Review, H1, 2014" provides data on the Pheochromocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pheochromocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pheochromocytoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Progenics Pharmaceuticals, Inc. - Nektar Therapeutics - Jubilant Life Sciences Limited - Insys Therapeutics, Inc. - GE Healthcare - National Cancer Institute - University of California, San Francisco - Seoul National University Hospital - Assistance Publique Hopitaux De Marseille - Cincinnati Children's Hospital Medical Center - European Organization for Research and Treatment of Cancer - University Medical Center Groningen - University of Southern California - Rouen University Hospital - University Hospital, Angers For more information visit http://www.researchandmarkets.com/research/mv...romocytoma

Progenics Finishes Patient Enrollment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 6:00PM CDT
Progenics Pharmaceuticals, Inc. (PGNX) completed patient enrollment in the second cohort of an ongoing phase II study on PSMA ADC for the treatment of prostate cancer.

Progenics Pharmaceuticals Announces the Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC
GlobeNewswire - Thu Apr 24, 9:16AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) an oncology company focused on the development of innovative approaches to targeting and treating prostate cancer, announced today the completion of enrollment in the chemotherapy naïve cohort in its Phase II trial of PSMA ADC. This cohort of 36 chemotherapy naïve prostate cancer patients, all of whom progressed on hormonal therapies, was added to the Phase II trial following positive response to PSMA ADC in patients in the chemotherapy experienced setting.

Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companes & 13 Drug Profiles
M2 - Wed Apr 23, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3fs6f/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Cubist Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Theravance, Inc. - Sucampo Pharmaceuticals, Inc. - AIKO Biotechnology, Inc. - Synergy Pharmaceuticals, Inc. - S.L.A. Pharma AG - Develco Pharma Schweiz AG Drug Profiles - naloxegol - lubiprostone - methylnaltrexone bromide - methylnaltrexone bromide - naldemedine - bevenopran - naloxone hydrochloride PR - methylnaltrexone bromide - TD-1211 - naloxone hydrochloride SR - SP-333 - naloxone hydrochloride - (6-beta-naltrexol oxycodone) For more information visit http://www.researchandmarkets.com/research/l3...oidinduced

Salix Pharmaceuticals and Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand the Use of RELISTOR in Chronic Non-Cancer Pain by the European Medicines Agency
Business Wire - Tue Apr 22, 6:01AM CDT
Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) and Progenics Pharmaceuticals, Inc. (Nasdaq GNX) announced today that the submission to the European Medicines Agency (EMA) of RELISTOR(R)(methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, has been accepted for review. If approved, this will add to the current marketing authorization in the European Union (EU), which allows for the use of RELISTOR(R) in advanced illness patients.

Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma

Global Neuroendocrine Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mssxcd/neuroendocrine) has announced the addition of the "Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Ipsen S.A. - F. Hoffmann-La Roche Ltd. - Progenics Pharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Threshold Pharmaceuticals, Inc. - Merck & Co., Inc. - Eli Lilly and Company - Daiichi Sankyo Company, Limited - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Stanford University - Grupo Espanol de Tumores Neuroendocrinos - University of Wisconsin Madison - The University of Iowa - University of California, San Francisco - Alberta Health Services Visit http://www.researchandmarkets.com/research/ms...oendocrine

Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 07, 11:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Mark R. Baker, CEO, will present at the 13th Annual Needham Healthcare Conference to be held April 8 and 9 at the Westin Grand Central Hotel in New York City. The presentation will take place on Tuesday, April 8 at 10:00 AM EST.

Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications
GlobeNewswire - Tue Apr 01, 11:36AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX), and Centre for Probe Development and Commercialization (CPDC) today announced that Azedra, a novel targeted radiotherapy candidate resuming phase 2 registrational testing in patients suffering from pheochromocytoma and paraganglioma, will be manufactured by CPDC for the developer of the compound, Progenics Pharmaceuticals.

Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register

Progenics Pharmaceuticals (PGNX): An Off-the-Radar Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:42AM CDT
Progenics Pharma looks well positioned for a solid gain, but has been overlooked by investors lately

Top Gainers Ahead of Market -- Research on Genco Shipping & Trading, Progenics Pharma, Rambus, and Exact Sciences
PR Newswire - Wed Mar 19, 7:05AM CDT
The US markets saw a positive sentiment on Tuesday, March 18, 2014, as the NASDAQ Composite closed at 4,333.31, up 1.25%, the Dow Jones Industrial Average ended the session at 16,336.19, up 0.55% and the S&P 500 edged 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Genco Shipping & Trading Ltd (NYSE: GNK), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rambus Inc. (NASDAQ: RMBS), and Exact Sciences Corp. (NASDAQ: EXAS). Free technical research on GNK, PGNX, RMBS, and EXAS can be downloaded upon signing up at:

Traders Get Bullish on Shares of Progenics Pharmaceuticals, Shares Up 8.3% (PGNX)
Comtex SmarTrend(R) - Tue Mar 18, 12:46PM CDT
Progenics Pharmaceuticals (NASDAQ GNX) is one of today's best performing low-priced stocks, up 8.3% to $4.69 on 1.0x average daily volume. Thus far today, Progenics Pharmaceuticals has traded 1.6 million shares, vs. average volume of 1.5 million shares per day. The stock has outperformed the Dow (8.3% to the Dow's 0.6%) and outperformed the S&P 500 (8.3% to the S&P's 0.7%) during today's trading.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 157

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 161

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 135

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 69

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 87

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 183

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 217

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 148

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading

Top 5 Most Recently Viewed Articles

Compugen's Q4 2025 Results: Is CGEN Set for a Rebound?

Updated Category News Views 168

Compugen Ltd. (NASDAQ: CGEN) is gearing up for its fourth quarter and full-year 2025 financial results set to drop on March 2, 2026, before U. S. markets open. You know how it goes—traders are already sizing up this number drop, trying to parse out if there’s any upside left or if it's just another 'waiting for Godot' situation. Compugen has been riding the waves of...

Continue Reading
Procyon Partners Appoints Rich Franchella to Propel Growth Strategy

Updated Category News Views 384

Procyon Partners' Strategic Growth Through Leadership Appointment Procyon Partners is excited to announce a significant addition to its leadership team with the appointment of Rich Franchella as the Senior Vice President of Business Development. This newly established role is aimed at catalyzing the firm’s growth trajectory and is set to bolster its efforts in...

Continue Reading
SMC Entertainment Expands Horizons With Bateau Acquisition

Updated Category News Views 162

SMC Entertainment Enhances Its Market Position SMC Entertainment, Inc. has taken a significant step in broadening its reach within the financial services sector by acquiring Bateau Asset Management. This strategic move paves the path for SMC to tap into the Australian and Southeast Asian markets, expanding its footprint in the dynamic world of fintech. An Overview of...

Continue Reading
Dustin Moskovitz Expands Asana Holdings with Major Purchase

Updated Category News Views 503

Dustin Moskovitz Expands His Investment in Asana Facebook co-founder Dustin A. Moskovitz, who currently holds the position of Director at Asana, Inc., has recently made headlines by increasing his stake in the company through the acquisition of 225,000 shares. This move highlights his ongoing commitment to the growth and success of Asana. Details of the Share Purchase The...

Continue Reading
GDMining's Innovative Cloud Mining Service Redefines Accessibility

Updated Category News Views 146

GDMining Expands Global Reach with Free Cloud Mining Service The cryptocurrency market is constantly evolving, and GDMining is leading the charge. This innovative platform offers an exciting opportunity for individuals around the globe to earn income from home through its unique cloud mining services. What sets this initiative apart is that it requires no initial...

Continue Reading